PolyNovo Limited (CALZF)
| Market Cap | 461.25M -10.7% |
| Revenue (ttm) | 93.04M +20.7% |
| Net Income | 6.59M +67.3% |
| EPS | 0.01 +67.6% |
| Shares Out | n/a |
| PE Ratio | 70.00 |
| Forward PE | 49.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 0.6200 |
| Previous Close | 0.6200 |
| Day's Range | 0.5600 - 0.6200 |
| 52-Week Range | 0.000001 - 1.0200 |
| Beta | 1.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About PolyNovo
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]
Financial Performance
In fiscal year 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.
Financial numbers in AUD Financial StatementsNews
PolyNovo Earnings release: Trading update
PolyNovo released its earnings on July 22, 2026, summarizing the period's financial results.
PolyNovo Earnings Call Transcript: H1 2026
Group sales rose 26% to AUD 68.2 million, led by strong U.S. and international growth, with Adjusted EBITDA up 82%. Manufacturing capacity expanded, clinical evidence base strengthened, and new markets targeted for further acceleration.
PolyNovo Quarterly report: H1 2026
PolyNovo has published its H1 2026 quarterly earnings report on February 19, 2026.
PolyNovo Slides: H1 2026
PolyNovo has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 19, 2026.
PolyNovo Slides: Investor Presentation
PolyNovo has posted slides in relation to its latest quarterly earnings report, which was published on November 17, 2025.
PolyNovo Transcript: AGM 2025
The meeting highlighted strong financial growth, global expansion, and robust product innovation, while addressing governance reforms and executive turnover. Shareholders raised concerns about transparency and board changes, with new leadership and strategic initiatives positioned for future growth.
PolyNovo Earnings Call Transcript: H2 2025
Record sales and profit growth were driven by strong U.S. and international demand, new product launches, and operational leverage. Cash flow and margins improved, with continued expansion into new markets and indications expected to sustain momentum.
PolyNovo Annual report: H2 2025
PolyNovo has published its H2 2025 annual report on August 25, 2025.
PolyNovo Slides: H2 2025
PolyNovo has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 25, 2025.